RxDoctor Payments DataLook up a doctor →

Daniel So, MD

Endocrinology, Diabetes & Metabolism · Arlington Heights, ILNPI 1023167004

Payments from drug & device makers

$283,075in general payments, 2019–2025

Across 1,604 payments — averaging $176.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$84K
  • Lilly USA, LLC$72K
  • Boehringer Ingelheim$70K
  • AstraZeneca$20K
  • AbbVie$17K
  • Dexcom, Inc.$3K
  • plus $17K from 54 others
$375in research payments, 2019–2025

Across 1 payment — averaging $375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Diabetes Care, Inc.$375

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC130$84,362
Lilly USA, LLC257$71,562
Boehringer Ingelheim174$69,768
AstraZeneca(2 entities)85$19,518
AbbVie48$17,120
Dexcom, Inc.90$3,238
Amgen(2 entities)72$1,723
Corcept Therapeutics52$1,608
Novo Nordisk94$1,565
Abbott111$1,390
Amneal Pharmaceuticals LLC48$857
Mannkind Corporation35$818
Antares Pharma, Inc.42$658
Esperion Therapeutics, Inc.23$633
OPKO Pharmaceuticals, LLC6$552
Bayer21$505
Xeris Pharmaceuticals, Inc.24$490
Neurocrine Biosciences, Inc.11$467
Medtronic(2 entities)14$461
Ascendis Pharma Endocrinology Inc16$430
Ascensia Diabetes Care US Inc.15$423
Tandem Diabetes Care, Inc.23$414
Merck25$409
Madrigal Pharmaceuticals11$348
Johnson & Johnson25$324
BETA Bionics, Inc.10$322
Amarin Pharma, Inc.10$296
IBSA Pharma Inc.18$288
Novartis12$273
Amryt Pharma Holdings Ltd9$263
Radius Health, Inc.9$181
Insulet Corporation6$169
Astellas Pharma US Inc6$146
Cequr Corporation2$142
Recordati_rare_diseases_inc.6$130
Ultragenyx Pharmaceutical Inc.6$100
Vivus LLC6$85
Halozyme Inc4$83
Kyowa Kirin, Inc.3$75
Shire North American Group Inc3$67
Nevro Corp.3$66
Verity Pharmaceuticals Inc.2$65
Lifescan, Inc.3$62
Amphastar Pharmaceuticals, Inc.3$60
Rhythm Pharmaceuticals, Inc.2$47
GSK3$46
Ipsen Biopharmaceuticals, Inc3$41
Echosens North America, Inc.2$40
Roche Diabetes Care, Inc.2$38
Zealand Pharma US, Inc.2$37
Clarus Therapeutics Inc.2$36
Azurity Pharmaceuticals, Inc.2$35
Organogenesis Inc.1$29
Jazz Pharmaceuticals Inc.1$28
Embecta Corp.1$27
Eisai Inc.1$23
BD1$22
Companion Medical, Inc.1$19
Valeritas, Inc.1$15
Acella Pharmaceuticals, LLC1$15

How this compares

$283,075 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024
$271,958
Medicare patients
923
Services billed
2,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Arlington Heights

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →